MENU

CAH Cardinal Health Forecast, Technical & Fundamental Analysis

Cardinal Health is one of three leading pharmaceutical wholesalers in the US, engaged in sourcing and distributing of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers... Show more

A.I.Advisor
Nov 08, 2026

Cardinal Health (CAH) Stock Forecast: Can Specialty and At-Home Growth Keep Driving the Story in 2027?

Key Takeaways

  • Specialty momentum is the core catalyst. Management has guided to double-digit specialty growth in fiscal 2027 after a roughly 25% surge in fiscal 2026, anchored by oncology, urology, and autoimmune (including gastroenterology) platforms.
  • Earnings guidance points to 13%–15% growth. Cardinal Health guided fiscal 2027 non-GAAP EPS to $12.40–$12.60, above its longer-term 12%–14% EPS growth framework.
  • At-home and precision health are scaling. The AdaptHealth diabetes business acquisition (expected to close in the second half of fiscal 2027) and the Strive Medical deal broaden the company's urology and continuous glucose monitoring footprint.
  • Capital allocation is supportive. The board raised buyback authorization by $5 billion to $6.4 billion, with at least $1 billion of repurchases planned in fiscal 2027 and adjusted free cash flow guided to $3.5–$4.0 billion.
  • Key sensitivities include the CVS renewal and tariffs. The year-end CVS distribution contract renewal and residual tariff and commodity-cost pressures in Global Medical Products and Distribution remain watch items.
  • Analyst consensus skews optimistic. Roughly 17 analysts rate the stock a consensus Buy, with average price targets clustered near $270–$292 and several firms (UBS, Morgan Stanley, RBC Capital) raising targets in late 2026.
  • For additional detail on Major News, Today's Price Move, Price Targets, and Earnings, explore Tickeron's dedicated pages for deeper context.
  • Explore Trending AI Robots to see automated strategies and AI-driven trading signals across the market.

Strategic Positioning and Competitive Outlook

Cardinal Health has progressively repositioned itself from a traditional pharmaceutical distributor into a diversified healthcare-services and infrastructure company. The centerpiece of that shift is its specialty strategy, which pairs core distribution with three physician-focused management services organization (MSO) platforms — oncology, urology, and autoimmune care — plus its fast-growing BioPharma Solutions commercialization business.

The competitive logic is structural: roughly 80%–90% of physicians in gastroenterology and urology remain unaffiliated with an MSO, leaving a large "white space" for bolt-on practice consolidation. Management has stated it does not need a fourth platform and instead plans to deepen existing verticals. This contrasts with peers McKesson and Cencora, which are pursuing broadly similar specialty expansion, meaning execution and margin discipline will determine relative outperformance.

At the same time, Cardinal Health is building scale in higher-margin adjacencies — Nuclear and Precision Health Solutions (including PET imaging and theranostics), at-Home Solutions, and OptiFreight Logistics. These businesses grew at a multiple of the core pharmaceutical segment and help diversify the earnings mix away from thin-margin drug distribution, though they carry higher integration risk as acquired assets are absorbed.

Major Catalysts Ahead

  • Fiscal 2027 earnings cadence. Following the Q1 fiscal 2027 report on November 5, 2026, investors will watch whether double-digit specialty growth and disciplined cost management keep EPS on track toward the $12.40–$12.60 guidance range.
  • The CVS distribution renewal. Management has described the relationship as "very strong," citing longer-dated partnerships in Red Oak Sourcing, biosimilars, and over-the-counter sourcing. A clean renewal would reduce a key overhang; any margin concession would be a negative signal.
  • AdaptHealth diabetes close and integration. Expected in the second half of fiscal 2027, this deal broadens continuous glucose monitoring (CGM) exposure, a market where only about 35% of eligible patients currently use a device.
  • Cell and gene therapy launches. New 3PL (third-party logistics) commercialization agreements position the company for therapies expected in fiscal 2028, with management noting it now services roughly three-quarters of the cell and gene market.
  • Analyst target revisions. Late-2026 updates have been broadly upward — UBS moved to $310, Morgan Stanley to $306, and RBC Capital to $295 — while consensus holds a Buy rating with average price targets near $291.53 (S&P Global) and no sell ratings.

Industry and Macroeconomic Forces

Cardinal Health's trajectory is tightly linked to healthcare utilization, demographics, and drug-pricing policy. An aging population supports the low-to-mid single-digit generic-volume baseline, while loss-of-exclusivity events in 2028–2029 are expected to provide constructive biosimilar and generic tailwinds.

Interest rates and inflation matter through two channels. Lower interest expense, supported by strong cash flow, is expected to aid fiscal 2027 earnings, while petroleum-based commodity costs and diesel prices pressure the Global Medical Products and Distribution segment. Management absorbed a $450 million tariff impact in fiscal 2026, mitigating about two-thirds through sourcing and operating actions — a reminder that trade policy remains a live variable.

On regulation, the Inflation Reduction Act's drug-pricing provisions create headline risk, but Cardinal Health's fee-for-service model and contractual protections have historically insulated its economics. Technology adoption — automation, advanced analytics, and digital ordering platforms — is emerging as a genuine efficiency lever across its distribution network.

Trend Prediction Engine

Tickeron's Trend Prediction Engine is an AI-powered forecasting tool that helps traders assess whether a stock, ETF, or other asset may trend bullish, bearish, or sideways over the coming week or month. It is designed to help users spot developing trends, evaluate potential breakouts or reversals, and explore predictions across a broad universe of tradable instruments. The product includes searchable prediction categories, historical context, and alert-oriented functionality to keep users informed of shifting signals. For investors tracking Cardinal Health alongside broader market momentum, the engine offers a data-driven way to monitor directional cues.

2026 Outlook and Long-Term Themes to Watch

Looking into 2026 and beyond, Cardinal Health's long-term value creation rests on its 12%–14% EPS growth target and an ambition to scale BioPharma Solutions revenue from $550 million in fiscal 2025 toward $1 billion by fiscal 2028. Structural drivers include the fragmentation of specialty physician practices, rising adoption of complex therapies, and expanding at-home care.

Margin sustainability will hinge on mix shift toward specialty, nuclear, and at-home businesses, which carry higher profitability than core distribution, balanced against elevated commodity costs and integration expenses. Capital allocation priorities — roughly $700 million of annual capital expenditures, at least $1 billion in buybacks, and disciplined tuck-in M&A — signal a shareholder-friendly but operationally focused playbook.

Key long-term risks include intensifying competition from McKesson and Cencora, potential policy changes around drug pricing, and execution risk on multiple simultaneous acquisitions. Consensus analyst expectations remain constructive, but the story increasingly depends on converting specialty and at-home scale into durable, above-market profit growth rather than relying on outsized one-year demand.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Interact to see
Advertisement
View a ticker or compare two or three
Interact to see
Advertisement
A.I. Advisor
published Earnings

CAH is expected to report earnings to fall 4.29% to $3.12 per share on February 04

Cardinal Health CAH Stock Earnings Reports
Q4'26
Est.
$3.12
Q3'26
Beat
by $0.34
Q2'26
Beat
by $0.19
Q1'26
Beat
by $0.38
Q4'25
Beat
by $0.32
The last earnings report on November 05 showed earnings per share of $3.26, beating the estimate of $2.92. With 583.28K shares outstanding, the current market capitalization sits at 62.92B.
A.I.Advisor
published Dividends

CAH paid dividends on October 15, 2026

Cardinal Health CAH Stock Dividends
А quarterly dividend of $0.52 per share was paid with a record date of October 15, 2026, and an ex-dividend date of October 01, 2026. Read more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
MWG1.450.03
+2.11%
Multi Ways Holdings Limited
AAMI88.141.17
+1.35%
Acadian Asset Management Inc
ZBH103.321.23
+1.20%
Zimmer Biomet Holdings
ROOT43.79-0.74
-1.66%
Root
EXOD3.42-0.39
-10.24%
Exodus Movement Inc

CAH and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, CAH has been closely correlated with MCK. These tickers have moved in lockstep 72% of the time. This A.I.-generated data suggests there is a high statistical probability that if CAH jumps, then MCK could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CAH
1D Price
Change %
CAH100%
-0.33%
MCK - CAH
72%
Closely correlated
-0.66%
COR - CAH
62%
Loosely correlated
-0.64%
HSIC - CAH
7%
Poorly correlated
+3.32%
AHG - CAH
4%
Poorly correlated
+3.17%
FOCL - CAH
2%
Poorly correlated
+9.15%
More

Groups containing CAH

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CAH
1D Price
Change %
CAH100%
-0.33%
CAH
(2 stocks)
80%
Closely correlated
-2.07%
A.I. Advisor
published General Information

General Information

a maker of pharmaceuticals, medical, surgical and laboratory supplies as well as develops drug delivery systems

Industry MedicalDistributors

Industry
Medical Distributors
Address
7000 Cardinal Place
Phone
+1 614 757-5000
Employees
63900
Web
https://www.cardinalhealth.com
Cardinal Health (CAH) Stock Forecast: Can Specialty and At-Home Growth Keep Driving the Story in 2027?